Publications by authors named "Arun A Azad"

Claim this Profile
P
Prognostic Value of Initial Imaging and PSA Change with [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
David C Chen, James P Buteau, Nathan Papa, Tim Akhurst, Ramin Alipour, Arun A Azad

J Nucl Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial.
Jane McKenzie, Arun A Azad

Eur Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [Ga]PSMA-11 or [F]DCFPyL, [F]FDG, and [Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.
Price Jackson, James P Buteau, Lachlan McIntosh, Yu Sun, Raghava Kashyap, Arun A Azad

J Nucl Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lutetium-177 [Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
Louise Kostos, James P Buteau, Jing Xie, Anthony Cardin, Tim Akhurst, Arun A Azad

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.
Yiyue Zhu, Elaheh Zarean, Danmeng L Li, Robert L O'Reilly, Ian D Davis, Arun A Azad

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Muhammad Ali, Mathias Bressel, David Chang, Sheng F Oon, Rajeev Ravi, Arun A Azad

BJU Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CONTACT-02: limited clinical benefit and a suboptimal control group - Authors' reply.
Neeraj Agarwal, Axel S Merseburger, Svetlana Andrianova, Arun A Azad

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [Lu]Lu-PSMA-617.
Heidi Fettke, Louise Kostos, Maria Docanto, Patricia Bukczynska, Nicole Ng, Arun A Azad

Eur Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.
Edmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, Louise Emmett, Shahneen Sandhu, Arun A Azad

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human results of terbium-161 [Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
James P Buteau, Louise Kostos, Price A Jackson, Jing Xie, Mohammad B Haskali, Arun A Azad

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.
Andrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, Arijit Ganguli, Vagia Daki, Arun A Azad

Future Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, André P Fay

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Neeraj Agarwal, Arun A Azad, Joan Carles, André P Fay, Nobuaki Matsubara

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
Neeraj Agarwal, Arun A Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of 20 Cycles of [Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Kerry E Jewell, James P Buteau, Elizabeth Medhurst, Edmond M Kwan, Shahneen Sandhu, Arun A Azad

J Nucl Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study.
Colin Williams, Andrisha-Jade Inderjeeth, Wei Hong, Jane McKenzie, Angelyn Anton, Arun A Azad

Clin Genitourin Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review.
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, Arun A Azad, Ciara Conduit

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell Engagers in Prostate Cancer.
Chadi Hage Chehade, Zeynep Irem Ozay, Micah Ostrowski, Chiara Mercinelli, Georges Gebrael, Arun A Azad

Eur Urol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.
Arun A Azad, Daniel P Petrylak, Taro Iguchi, Neal D Shore, Arnauld Villers

JAMA Netw Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study.
Cristian Udovicich, Mathias Bressel, Jamil Manji, Muhammad Ali, Lewis Au, Arun A Azad

J Nucl Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-Related Myeloid Neoplasms After [Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.
Michal Eifer, Duncan E K Sutherland, Isaac Goncalves, James P Buteau, Lewis Au, Arun A Azad

J Nucl Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, Fred Saad, Ugo De Giorgi

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, Arun A Azad, Fred Saad

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.
Arun A Azad, Howard Gurney, Craig Underhill, Lisa Horvath, Mark Voskoboynik

Invest New Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis